PRMT5 Inhibitors via Local Quality and Segmentation

The patent applies local quality by designing inhibitors with specific molecular features (e.g., heterocyclic rings, hydrogen bonding capabilities) that interact with unique structural characteristics of PRMT5's S-adenosylhomocysteine (SAH) binding pocket. This localized molecular recognition ensures high selectivity for PRMT5 while minimizing off-target effects on other methyltransferases, thereby resolving the contradiction between therapeutic efficacy and selectivity.

The patent employs parameter changes by systematically varying key molecular parameters of the inhibitors, including heteroatom types (N, O, S), ring sizes, substitution patterns, and hydrogen bonding donors/acceptors. These parameter optimizations fine-tune the binding affinity and selectivity for PRMT5, enabling potent inhibition with minimal cross-reactivity to other enzymes, thus achieving both high efficacy and safety.

The patent applies segmentation by dividing the inhibitor molecule into distinct functional modules: a heterocyclic core structure for PRMT5 binding, hydrophobic aromatic groups for membrane penetration, and polar substituents for solubility. This modular design enables systematic optimization of each segment's properties to achieve the desired balance between cellular uptake and manageable molecular complexity.

The patent uses aromatic hydrocarbon intermediaries (e.g., phenyl, naphthyl groups) as mediators that facilitate membrane penetration while maintaining manageable molecular complexity. These intermediary structures serve as versatile building blocks that can be systematically modified to tune lipophilicity and cellular permeability without requiring overly complex molecular architectures.

The patent applies universality by designing a core heterocyclic scaffold (e.g., pyrimidine, triazine, pyridine rings) that serves multiple functions: binding to the PRMT5 SAH pocket, providing a platform for diverse substituent attachment, and maintaining appropriate physicochemical properties. This universal scaffold approach enables efficient structure-activity relationship (SAR) exploration across multiple derivatives without requiring de novo design for each compound, thereby reducing development time while maintaining high effectiveness.

The patent employs preliminary action by pre-optimizing the core heterocyclic structure and key substituent positions based on computational modeling and preliminary biochemical screening. This preliminary structuring establishes a validated framework that guides subsequent synthesis and testing, reducing the need for extensive trial-and-error and accelerating the identification of effective inhibitors.